Denise L Doolan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1127280/publications.pdf

Version: 2024-02-01

153 papers	9,158 citations	57758 44 h-index	46799 89 g-index
159 all docs	159 docs citations	159 times ranked	8068 citing authors

#	Article	IF	Citations
1	Acquired Immunity to Malaria. Clinical Microbiology Reviews, 2009, 22, 13-36.	13.6	981
2	Induction of Antigen-Specific Cytotoxic T Lymphocytes in Humans by a Malaria DNA Vaccine. Science, 1998, 282, 476-480.	12.6	761
3	Protection of Humans against Malaria by Immunization with Radiationâ€AttenuatedPlasmodium falciparumSporozoites. Journal of Infectious Diseases, 2002, 185, 1155-1164.	4.0	652
4	A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6958-6963.	7.1	412
5	The Complexity of Protective Immunity Against Liver-Stage Malaria. Journal of Immunology, 2000, 165, 1453-1462.	0.8	313
6	Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics, 2008, 8, 4680-4694.	2.2	236
7	Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9952-9957.	7.1	227
8	The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Frontiers in Immunology, 2020, 11, 303.	4.8	219
9	Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine, 2000, 18, 1893-1901.	3.8	212
10	Degenerate Cytotoxic T Cell Epitopes from P. falciparum Restricted by Multiple HLA-A and HLA-B Supertype Alleles. Immunity, 1997, 7, 97-112.	14.3	190
11	Immune effector mechanisms in malaria. Current Opinion in Immunology, 1999, 11, 412-419.	5.5	179
12	Suboptimal SARS-CoV-2â^'specific CD8 ⁺ T cell response associated with the prominent HLA-A*02:01 phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24384-24391.	7.1	168
13	HLA-DR-Promiscuous T Cell Epitopes fromPlasmodiumâ€^falciparumPre-Erythrocytic-Stage Antigens Restricted by Multiple HLA Class II Alleles. Journal of Immunology, 2000, 165, 1123-1137.	0.8	134
14	Sterile Protective Immunity to Malaria is Associated with a Panel of Novel P. falciparum Antigens. Molecular and Cellular Proteomics, 2011, 10, M111.007948.	3.8	134
15	DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity. PLoS ONE, 2013, 8, e55571.	2.5	127
16	Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nature Communications, 2021, 12, 2037.	12.8	125
17	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Reports Medicine, 2021, 2, 100208.	6.5	115
18	CD8+ TÂcells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. Immunity, 2021, 54, 1066-1082.e5.	14.3	106

#	Article	IF	Citations
19	DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation. International Journal for Parasitology, 2001, 31, 753-762.	3.1	100
20	Induction in Humans of CD8+ and CD4+ T Cell and Antibody Responses by Sequential Immunization with Malaria DNA and Recombinant Protein. Journal of Immunology, 2004, 172, 5561-5569.	0.8	97
21	Identification of humoral immune responses in protein microarrays using DNA microarray data analysis techniques. Bioinformatics, 2006, 22, 1760-1766.	4.1	93
22	Plasmodium immunomics. International Journal for Parasitology, 2011, 41, 3-20.	3.1	91
23	Development and validation of serological markers for detecting recent Plasmodium vivax infection. Nature Medicine, 2020, 26, 741-749.	30.7	90
24	Malaria Vaccine Design: ImmunologicalÂConsiderations. Immunity, 2010, 33, 555-566.	14.3	89
25	Type I Interferons Regulate Immune Responses in Humans with Blood-Stage Plasmodium falciparum Infection. Cell Reports, 2016, 17, 399-412.	6.4	88
26	Estimating the global burden of Epsteinâ€“Barr virus-related cancers. Journal of Cancer Research and Clinical Oncology, 2022, 148, 31-46.	2.5	84
27	Identification and Characterization of the Protective Gene of homolog of Exported Protein 1. Journal of Biological Chemistry, 1996, 271, 17861-17868.	3.4	81
28	The Stability and Complexity of Antibody Responses to the Major Surface Antigen of Plasmodium falciparum Are Associated with Age in a Malaria Endemic Area. Molecular and Cellular Proteomics, 2011, 10, M111.008326.	3.8	78
29	An Immunomics Approach to Schistosome Antigen Discovery: Antibody Signatures of Naturally Resistant and Chronically Infected Individuals from Endemic Areas. PLoS Pathogens, 2014, 10, e1004033.	4.7	78
30	Non-toxic derivatives of LT as potent adjuvants. Vaccine, 2011, 29, 1538-1544.	3.8	75
31	Determining liver stage parasite burden by real time quantitative PCR as a method for evaluating pre-erythrocytic malaria vaccine efficacy. Molecular and Biochemical Parasitology, 2001, 118, 233-245.	1.1	71
32	Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component. PLoS ONE, 2011, 6, e25868.	2.5	70
33	Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults. PLoS ONE, 2011, 6, e24586.	2.5	63
34	Viral vectors for malaria vaccine development. Vaccine, 2007, 25, 2567-2574.	3.8	62
35	Simultaneous Induction of Multiple Antigen-Specific Cytotoxic T Lymphocytes in Nonhuman Primates by Immunization with a Mixture of FourPlasmodium falciparumDNA Plasmids. Infection and Immunity, 1998, 66, 4193-4202.	2.2	62
36	Location of human cytotoxic T cell epitopes within a polymorphic domain of the Plasmodium falciparum circumsporozoite protein. International Immunology, 1991, 3, 511-516.	4.0	60

#	Article	IF	Citations
37	Schistosomiasis vaccine discovery using immunomics. Parasites and Vectors, 2010, 3, 4.	2.5	57
38	Malaria vaccinesâ€“targeting infected hepatocytes. Nature Medicine, 2000, 6, 1218-1219.	30.7	56
39	Large screen approaches to identify novel malaria vaccine candidates. Vaccine, 2015, 33, 7496-7505.	3.8	54
40	Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan. Clinical Cancer Research, 2018, 24, 1305-1314.	7.0	52
41	CD4⁺T-Cell- and Gamma Interferon-Dependent Protection against Murine Malaria by Immunization with Linear Synthetic Peptides from aPlasmodium yoelii17-Kilodalton Hepatocyte Erythrocyte Protein. Infection and Immunity, 1999, 67, 5604-5614.	2.2	50
42	Polyfunctional and IFN-Î³ monofunctional human CD4+ T cell populations are molecularly distinct. JCI Insight, 2017, 2, e87499.	5.0	50
43	Vaccinomics for the Major Blood Feeding Helminths of Humans. OMICS A Journal of Integrative Biology, 2011, 15, 567-577.	2.0	48
44	Probing of a Human Proteome Microarray With a Recombinant Pathogen Protein Reveals a Novel Mechanism by Which Hookworms Suppress B-Cell Receptor Signaling. Journal of Infectious Diseases, 2015, 211, 416-425.	4.0	47
45	Sterile Protection against Plasmodium knowlesi in Rhesus Monkeys from a Malaria Vaccine: Comparison of Heterologous Prime Boost Strategies. PLoS ONE, 2009, 4, e6559.	2.5	46
46	Clinical trial in healthy malaria-naÃ¯ve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stagePlasmodium falciparumDNA vaccine combined with escalating dose human GM-CSF DNA. Human Vaccines and Immunotherapeutics, 2012, 8, 1564-1584.	3.3	44
47	Of Monkeys and Men: Immunomic Profiling of Sera from Humans and Non-Human Primates Resistant to Schistosomiasis Reveals Novel Potential Vaccine Candidates. Frontiers in Immunology, 2015, 6, 213.	4.8	43
48	Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults. Malaria Journal, 2011, 10, 168.	2.3	41
49	Protective Immunity against Severe Malaria in Children Is Associated with a Limited Repertoire of Antibodies to Conserved PfEMP1 Variants. Cell Host and Microbe, 2019, 26, 579-590.e5.	11.0	40
50	Cytotoxic T lymphocyte (CTL) low-responsiveness to the Plasmodium falciparum circumsporozoite protein in naturally-exposed endemic populations: analysis of human CTL response to most known variants. International Immunology, 1993, 5, 37-46.	4.0	39
51	Genome-based vaccine design: the promise for malaria and other infectious diseases. International Journal for Parasitology, 2014, 44, 901-913.	3.1	39
52	Preâ€“erythrocyticâ€“stage immune effector mechanisms in Plasmodium spp. infections. Philosophical Transactions of the Royal Society B: Biological Sciences, 1997, 352, 1361-1367.	4.0	38
53	Persistence of Protective Immunity to Malaria Induced by DNA Priming and Poxvirus Boosting: Characterization of Effector and Memory CD8+-T-Cell Populations. Infection and Immunity, 2002, 70, 3493-3499.	2.2	38
54	Expression of the chemokine MIG is a sensitive and predictive marker for antigen-specific, genetically restricted IFN-Î³ production and IFN-Î³-secreting cells. Journal of Immunological Methods, 2001, 257, 55-69.	1.4	37

#	Article	IF	Citations
55	Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation. Vaccine, 2007, 25, 6635-6645.	3.8	37
56	The US Capitol Bioterrorism Anthrax Exposures: Clinical Epidemiological and Immunological Characteristics. Journal of Infectious Diseases, 2007, 195, 174-184.	4.0	36
57	IFN-Î³ Inhibits IL-4â€“Induced Type 2 Cytokine Expression by CD8 T Cells In Vivo and Modulates the Anti-Tumor Response. Journal of Immunology, 2010, 185, 998-1004.	0.8	35
58	Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth. Vaccine, 2010, 28, 3201-3210.	3.8	35
59	Human challenge models: tools to accelerate the development of malaria vaccines. Expert Review of Vaccines, 2019, 18, 241-251.	4.4	35
60	Harnessing immune responses against Plasmodium for rational vaccine design. Trends in Parasitology, 2011, 27, 274-283.	3.3	32
61	Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization. Malaria Journal, 2007, 6, 135.	2.3	31
62	Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-Existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses. PLoS ONE, 2012, 7, e33920.	2.5	31
63	Chemically Attenuated Blood-Stage Plasmodium yoelii Parasites Induce Long-Lived and Strain-Transcending Protection. Infection and Immunity, 2016, 84, 2274-2288.	2.2	31
64	Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines. Immunology Letters, 2007, 111, 92-102.	2.5	30
65	The Role of Age and Exposure to Plasmodium falciparum in the Rate of Acquisition of Naturally Acquired Immunity: A Randomized Controlled Trial. PLoS ONE, 2012, 7, e32362.	2.5	30
66	Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP). Malaria Journal, 2013, 12, 185.	2.3	30
67	Reduced Plasmodium Parasite Burden Associates with CD38+ CD4+ T Cells Displaying Cytolytic Potential and Impaired IFN-Î³ Production. PLoS Pathogens, 2016, 12, e1005839.	4.7	30
68	Extended immunization intervals enhance the immunogenicity and protective efficacy of plasmid DNA vaccines. Microbes and Infection, 2007, 9, 1439-1446.	1.9	29
69	Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein. Malaria Journal, 2010, 9, 241.	2.3	29
70	Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity. Malaria Journal, 2016, 15, 377.	2.3	29
71	Dichotomous miR expression and immune responses following primary blood-stage malaria. JCI Insight, 2017, 2, .	5.0	29
72	A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine, 2021, 74, 103729.	6.1	29

#	Article	IF	Citations
73	Robust correlations across six SARSâ€CoVâ€2 serology assays detecting distinct antibody features. Clinical and Translational Immunology, 2021, 10, e1258.	3.8	28
74	Uptake of Schistosoma mansoni extracellular vesicles by human endothelial and monocytic cell lines and impact on vascular endothelial cell gene expression. International Journal for Parasitology, 2020, 50, 685-696.	3.1	27
75	High-throughput multi-parameter flow-cytometric analysis from micro-quantities of Plasmodium-infected blood. International Journal for Parasitology, 2011, 41, 1285-1294.	3.1	26
76	Evidence for limited activation of distinct CD4+T cell subsets in response to the Plasmodium falciparum circumsporozoite protein in Papua New Guinea. Parasite Immunology, 1994, 16, 129-136.	1.5	25
77	Toward clinical trials of DNA vaccines against malaria. Immunology and Cell Biology, 1997, 75, 376-381.	2.3	25
78	Defining the targets of antiparasitic compounds. Drug Discovery Today, 2016, 21, 725-739.	6.4	25
79	The case for a rational genome-based vaccine against malaria. Frontiers in Microbiology, 2015, 5, 741.	3.5	24
80	Antibody Signatures Reflect Different Disease Pathologies in Patients With Schistosomiasis Due toSchistosoma japonicum. Journal of Infectious Diseases, 2016, 213, 122-130.	4.0	24
81	Plasmacytoid dendritic cells appear inactive during sub-microscopic Plasmodium falciparum blood-stage infection, yet retain their ability to respond to TLR stimulation. Scientific Reports, 2017, 7, 2596.	3.3	24
82	Plasmodium vivax but Not Plasmodium falciparum Blood-Stage Infection in Humans Is Associated with the Expansion of a CD8+ T Cell Population with Cytotoxic Potential. PLoS Neglected Tropical Diseases, 2016, 10, e0005031.	3.0	24
83	The Association between the Comprehensive Epsteinâ€“Barr Virus Serologic Profile and Endemic Burkitt Lymphoma. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 57-62.	2.5	23
84	A Novel Candidate Vaccine for Cytauxzoonosis Inferred from Comparative Apicomplexan Genomics. PLoS ONE, 2013, 8, e71233.	2.5	22
85	Mining, visualizing and comparing multidimensional biomolecular data using the Genomics Data Miner (GMine) Web-Server. Scientific Reports, 2016, 6, 38178.	3.3	22
86	Systems Approaches towards Molecular Profiling of Human Immunity. Trends in Immunology, 2016, 37, 53-67.	6.8	22
87	Profoundly Reduced CD1c ⁺ Myeloid Dendritic Cell HLA-DR and CD86 Expression and Increased Tumor Necrosis Factor Production in Experimental Human Blood-Stage Malaria Infection. Infection and Immunity, 2016, 84, 1403-1412.	2.2	22
88	Early Immune Regulatory Changes in a Primary Controlled Human Plasmodium vivax Infection: CD1c ⁺ Myeloid Dendritic Cell Maturation Arrest, Induction of the Kynurenine Pathway, and Regulatory T Cell Activation. Infection and Immunity, 2017, 85, .	2.2	22
89	A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. Journal of Infectious Diseases, 2021, 223, 10-14.	4.0	21
90	Class I HLA-restricted cytotoxic T lymphocyte responses against malaria-elucidation on the basis of HLA peptide binding motifs. Immunologic Research, 1996, 15, 280-305.	2.9	20

#	Article	IF	Citations
91	Vaxfectinâ„¢ enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine, 2006, 24, 1921-1927.	3.8	20
92	Vaccination with Lipid Core Peptides Fails to Induce Epitope-Specific T Cell Responses but Confers Non-Specific Protective Immunity in a Malaria Model. PLoS ONE, 2012, 7, e40928.	2.5	20
93	Protein Microarrays for Parasite Antigen Discovery. Methods in Molecular Biology, 2015, 1201, 221-233.	0.9	20
94	Simultaneous Induction of Multiple Antigen-Specific Cytotoxic T Lymphocytes in Nonhuman Primates by Immunization with a Mixture of Four Plasmodium falciparum DNA Plasmids. Infection and Immunity, 1998, 66, 4193-4202.	2.2	20
95	Nucleic Acid Vaccines against Malaria. , 2002, 80, 308-321.		19
96	Immunomics: a 21st century approach to vaccine development for complex pathogens. Parasitology, 2016, 143, 236-244.	1.5	19
97	Defined Small Molecules Produced by Himalayan Medicinal Plants Display Immunomodulatory Properties. International Journal of Molecular Sciences, 2018, 19, 3490.	4.1	19
98	Immunization with Apical Membrane Antigen 1 Confers Sterile Infection-Blocking Immunity against Plasmodium Sporozoite Challenge in a Rodent Model. Infection and Immunity, 2013, 81, 3586-3599.	2.2	18
99	Anomalies in T Cell Function Are Associated With Individuals at Risk of Mycobacterium abscessus Complex Infection. Frontiers in Immunology, 2018, 9, 1319.	4.8	18
100	Subcutaneous cholera toxin exposure induces potent <scp>CD</scp>103⁺ dermal dendritic cell activation and migration. European Journal of Immunology, 2013, 43, 2707-2717.	2.9	16
101	A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP1 ₄₂ in a Prime/Boost Heterologous Immunization Regimen Partially Protects Aotus Monkeys against Blood-Stage Challenge. Vaccine Journal, 2017, 24, .	3.1	16
102	Novel Plasmodium antigens identified via genome-based antibody screen induce protection associated with polyfunctional T cell responses. Scientific Reports, 2017, 7, 15053.	3.3	16
103	Immune Signature Against Plasmodium falciparum Antigens Predicts Clinical Immunity in Distinct Malaria Endemic Communities. Molecular and Cellular Proteomics, 2020, 19, 101-113.	3.8	16
104	Plasmodium: Mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity. Experimental Parasitology, 2009, 122, 112-123.	1.2	15
105	Evaluation of the antibody response to the EBV proteome in EBVâ€associated classical Hodgkin lymphoma. International Journal of Cancer, 2020, 147, 608-618.	5.1	15
106	VaxfectinÂ® enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses. Vaccine, 2010, 28, 3055-3065.	3.8	14
107	Genome- and proteome-wide screening strategies for antigen discovery and immunogen design. Biotechnology Advances, 2014, 32, 403-414.	11.7	14
108	Recent advances in proteomic applications for schistosomiasis research: potential clinical impact. Expert Review of Proteomics, 2017, 14, 171-183.	3.0	14

#	Article	IF	Citations
109	Validation of an Epstein-Barr Virus Antibody Risk Stratification Signature for Nasopharyngeal Carcinoma by Use of Multiplex Serology. Journal of Clinical Microbiology, 2020, 58, .	3.9	14
110	Immunomics-guided discovery of serum and urine antibodies for diagnosing urogenital schistosomiasis: a biomarker identification study. Lancet Microbe, The, 2021, 2, e617-e626.	7.3	14
111	Evaluation of Approaches to Identify the Targets of Cellular Immunity on a Proteome-Wide Scale. PLoS ONE, 2011, 6, e27666.	2.5	14
112	Transcriptionally active PCR for antigen identification and vaccine development: In vitro genome-wide screening and in vivo immunogenicity. Molecular and Biochemical Parasitology, 2008, 158, 32-45.	1.1	13
113	Patterns of Interindividual Variability in the Antibody Repertoire Targeting Proteins Across the Epstein-Barr Virus Proteome. Journal of Infectious Diseases, 2018, 217, 1923-1931.	4.0	13
114	High production of pro-inflammatory cytokines by maternal blood mononuclear cells is associated with reduced maternal malaria but increased cord blood infection. Malaria Journal, 2018, 17, 177.	2.3	13
115	Deciphering host immunity to malaria using systems immunology. Immunological Reviews, 2020, 293, 115-143.	6.0	13
116	Toward a Surrogate Marker of Malaria Exposure: Modeling Longitudinal Antibody Measurements under Outbreak Conditions. PLoS ONE, 2011, 6, e21826.	2.5	12
117	Synthesis of Mannosylated Lipopeptides with Receptor Targeting Properties. Bioconjugate Chemistry, 2016, 27, 533-548.	3.6	12
118	Systematic evaluation of self-adjuvanting lipopeptide nano-vaccine platforms for the induction of potent CD8+T-cell responses. Nanomedicine, 2016, 11, 137-152.	3.3	12
119	Highly Sensitive Quantitative Real-Time PCR for the Detection of Plasmodium Liver-Stage Parasite Burden following Low-Dose Sporozoite Challenge. PLoS ONE, 2013, 8, e77811.	2.5	11
120	Chimeric Murine Polyomavirus Virus-Like Particles Induce Plasmodium Antigen-Specific CD8+ T Cell and Antibody Responses. Frontiers in Cellular and Infection Microbiology, 2019, 9, 215.	3.9	11
121	Human T cell recognition of the blood stage antigen Plasmodium hypoxanthine guanine xanthine phosphoribosyl transferase (HGXPRT) in acute malaria. Malaria Journal, 2009, 8, 122.	2.3	10
122	Intermittent preventive treatment with sulfadoxine-pyrimethamine does not modify plasma cytokines and chemokines or intracellular cytokine responses to Plasmodium falciparum in Mozambican Children. BMC Immunology, 2012, 13, 5.	2.2	10
123	Synthesis and Characterisation of Selfâ€Assembled and Selfâ€Adjuvanting Asymmetric Multiâ€Epitope Lipopeptides of Ovalbumin. Chemistry - A European Journal, 2015, 21, 1251-1261.	3.3	10
124	Identification of Cytauxzoon felis antigens via protein microarray and assessment of expression library immunization against cytauxzoonosis. Clinical Proteomics, 2018, 15, 44.	2.1	10
125	An Analytically and Diagnostically Sensitive RNA Extraction and RT-qPCR Protocol for Peripheral Blood Mononuclear Cells. Frontiers in Immunology, 2020, 11, 402.	4.8	10
126	Influence of Physicochemical Properties of Lipopeptide Adjuvants on the Immune Response: A Rationale for Engineering a Potent Vaccine. Chemistry - A European Journal, 2018, 24, 9892-9902.	3.3	9

#	Article	IF	Citations
127	Specific humoral response of hosts with variable schistosomiasis susceptibility. Immunology and Cell Biology, 2016, 94, 52-65.	2.3	8
128	Multilaboratory Assessment of Epstein-Barr Virus Serologic Assays: the Case for Standardization. Journal of Clinical Microbiology, 2019, 57, .	3.9	8
129	A Balanced Proinflammatory and Regulatory Cytokine Signature in Young African Children Is Associated With Lower Risk of Clinical Malaria. Clinical Infectious Diseases, 2019, 69, 820-828.	5.8	8
130	Malaria's journey through the lymph node. Nature Medicine, 2007, 13, 1023-1024.	30.7	7
131	Profiling the Targets of Protective CD8+ T Cell Responses to Infection. Molecular Therapy - Methods and Clinical Development, 2017, 7, 20-31.	4.1	7
132	A novel population of memoryâ€activated natural killer cells associated with low parasitaemia in Plasmodium falciparumâ€exposed sickleâ€cell trait children. Clinical and Translational Immunology, 2020, 9, e1125.	3.8	7
133	Proteomic identification of the contents of small extracellular vesicles from in vivo Plasmodium yoelii infection. International Journal for Parasitology, 2022, 52, 35-45.	3.1	6
134	HLA degenerate T-cell epitopes from Plasmodium falciparum liver stage-specific antigen 1 (LSA-1) are highly conserved in isolates from geographically distinct areas. Parasite Immunology, 2000, 22, 469-473.	1.5	5
135	Development of a cytokine-secreting-based assay for the identification, sorting and transcriptomic analysis of polyfunctional human T cells. European Cytokine Network, 2015, 26, 67-72.	2.0	4
136	Characterization of the humoral immune response to the EBV proteome in extranodal NK/T-cell lymphoma. Scientific Reports, 2021, 11, 23664.	3.3	4
137	A population of CD4 hi CD38 hi T cells correlates with disease severity in patients with acute malaria. Clinical and Translational Immunology, 2020, 9, e1209.	3.8	3
138	Chimeric Virus-Like Particles and Capsomeres Induce Similar CD8+ T Cell Responses but Differ in Capacity to Induce CD4+ T Cell Responses and Antibody Responses. Frontiers in Immunology, 2020, 11, 564627.	4.8	3
139	CD161 expression defines new human Î³Î´ T cell subsets. Immunity and Ageing, 2022, 19, 11.	4.2	3
140	Identification of the Glycan Binding Profile of Human and Rodent Plasmodium Sporozoites. ACS Infectious Diseases, 2021, 7, 2383-2389.	3.8	2
141	Malaria research in Australia: looking through the lens of the past towards the future. International Journal for Parasitology, 2021, 51, 1255-1263.	3.1	2
142	Editorial: Coronavirus Disease (COVID-19): Pathophysiology, Epidemiology, Clinical Management and Public Health Response. Frontiers in Public Health, 2021, 9, 807159.	2.7	2
143	The Australasian Contribution to Malaria Vaccine Development. Parasite Immunology, 2010, 32, no-no.	1.5	1
144	Addressing the bottleneck at clinical testing of candidate malaria vaccines. Pathogens and Global Health, 2012, 106, 321-322.	2.3	1

#	Article	IF	Citations
145	Memory CD8⁺ T cell compartment associated with delayed onset of Plasmodium falciparum infection and better parasite control in sickleâ€cell trait children. Clinical and Translational Immunology, 2021, 10, e1265.	3.8	1
146	Assessing Antigen-Specific CD8⁺ CTL Responses in Humans. , 2002, 72, 445-456.		0
147	The path of discovery. Hum Vaccin, 2008, 4, 324-327.	2.4	0
148	Editorial. International Journal for Parasitology: Drugs and Drug Resistance, 2011, 1, 1.	3.4	0
149	Editorial. International Journal for Parasitology: Parasites and Wildlife, 2012, 1, 1.	1.5	0
150	Casting a Wide Net around Immunity to Malaria Catches p53. Immunity, 2019, 51, 603-605.	14.3	0
151	2018 ISV Congress: advances in the 100 years since the worldâ€™s deadliest pandemic. Human Vaccines and Immunotherapeutics, 2019, 15, 2006-2008.	3.3	0
152	Protective Immunity Against Severe Malaria is Associated with a Repertoire of Antibodies to Conserved PfEMP1 Variants. SSRN Electronic Journal, 0, , .	0.4	0
153	Identifying Epstein-Barr virus peptide sequences associated with differential IgG antibody response. International Journal of Infectious Diseases, 2021, 114, 65-71.	3.3	0